Why Did Revolution Medicines (RVMD) Stock Soar Today?

Revolution Medicines (RVMD) stock surged on Monday after the clinical-stage precision oncology company revealed incredible details from a Phase 3 clinical trial of daraxonrasib. This is a treatment candidate for patients with metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer that is also highly aggressive.

Revolution Medicines reported that daraxonrasib taken orally once a day showed “statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy delivered intravenously.” Patients in the trial experienced a median OS of 13.2 months, compared to 6.7 months for chemotherapy.

Considering the positive results from the Phase 3 clinical trial of daraxonrasib, Revolution Medicines intends to submit a New Drug Application to the U.S. Food and Drug Administration (FDA). The company intends to do so through the Commissioner’s National Priority Voucher. It will also share more results from the study at the 2026 American Society of Clinical Oncology Annual Meeting.

Revolution Medicines Stock Movement Today

Revolution Medicines stock was up 25.94% on Monday, extending a 70.12% rally year-to-date. The shares have also gained 164.41% over the past 12 months.

RVMD stock also experienced heavy trading alongside today’s clinical trial results. This saw some 3.41 million shares change hands, compared to a three-month average daily trading volume of about 1.78 million shares.

Is Revolution Medicines Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Revolution Medicines is Strong Buy, based on 17 Buy ratings over the past three months. With that comes an average RVMD stock price target of $141.67, representing a potential 7.54% upside for the shares.